PL2948559T3 - Antagonisty kv1.3 i sposoby zastosowania - Google Patents

Antagonisty kv1.3 i sposoby zastosowania

Info

Publication number
PL2948559T3
PL2948559T3 PL14743871T PL14743871T PL2948559T3 PL 2948559 T3 PL2948559 T3 PL 2948559T3 PL 14743871 T PL14743871 T PL 14743871T PL 14743871 T PL14743871 T PL 14743871T PL 2948559 T3 PL2948559 T3 PL 2948559T3
Authority
PL
Poland
Prior art keywords
antagonists
methods
application
Prior art date
Application number
PL14743871T
Other languages
English (en)
Inventor
Ellen Chi
Wilson EDWARDS
Chichi Huang
Wai-Ping Leung
Ronald Swanson
Alan Wickenden
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PL2948559T3 publication Critical patent/PL2948559T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
PL14743871T 2013-01-25 2014-01-24 Antagonisty kv1.3 i sposoby zastosowania PL2948559T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361756777P 2013-01-25 2013-01-25
US201361757389P 2013-01-28 2013-01-28
PCT/US2014/012932 WO2014116937A1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use
EP14743871.7A EP2948559B1 (en) 2013-01-25 2014-01-24 Kv1.3 antagonists and methods of use

Publications (1)

Publication Number Publication Date
PL2948559T3 true PL2948559T3 (pl) 2018-09-28

Family

ID=51228060

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14743871T PL2948559T3 (pl) 2013-01-25 2014-01-24 Antagonisty kv1.3 i sposoby zastosowania

Country Status (29)

Country Link
US (2) US10179808B2 (pl)
EP (1) EP2948559B1 (pl)
JP (1) JP6469590B2 (pl)
KR (1) KR102268830B1 (pl)
CN (1) CN104937105A (pl)
AU (1) AU2014209227B2 (pl)
BR (1) BR112015017795A2 (pl)
CA (1) CA2898496A1 (pl)
CY (1) CY1120481T1 (pl)
DK (1) DK2948559T3 (pl)
EA (1) EA037308B1 (pl)
ES (1) ES2671434T3 (pl)
HR (1) HRP20181055T1 (pl)
HU (1) HUE039465T2 (pl)
IL (1) IL239927B (pl)
LT (1) LT2948559T (pl)
MX (1) MX365987B (pl)
NZ (1) NZ709913A (pl)
PH (1) PH12015501627B1 (pl)
PL (1) PL2948559T3 (pl)
PT (1) PT2948559T (pl)
RS (1) RS57422B1 (pl)
SG (1) SG11201505508TA (pl)
SI (1) SI2948559T1 (pl)
SM (1) SMT201800357T1 (pl)
TR (1) TR201809377T4 (pl)
UA (1) UA117824C2 (pl)
WO (1) WO2014116937A1 (pl)
ZA (1) ZA201506131B (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180365B1 (en) * 2014-08-15 2021-08-18 Monash University Novel potassium channel blockers and use thereof in the treatment of autoimmune diseases
WO2016141266A1 (en) 2015-03-05 2016-09-09 President And Fellows Of Harvard College Compliant adaptive robot grasper
CN109862907A (zh) * 2016-05-02 2019-06-07 泰特拉基因股份有限公司 抗Kv1.3抗体及其生产方法和用途
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
TW201808987A (zh) 2016-06-08 2018-03-16 健生生物科技公司 Ｇｍ－ｃｓｆ變體及使用方法
CN106589092A (zh) * 2016-12-22 2017-04-26 中国科学技术大学先进技术研究院 一种蝎毒素多肽及制备拥有类似天然生理功能的蝎毒素多肽的方法
CN106957357B (zh) * 2017-04-01 2021-02-19 合肥科生景肽生物科技有限公司 一种蝎毒素多肽及其合成方法
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
WO2021053194A1 (en) 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers
US20240182531A1 (en) 2021-03-23 2024-06-06 Zealand Pharma A/S KV1.3 Blockers
EP4604984A1 (en) 2022-10-18 2025-08-27 Zealand Pharma A/S Inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
GB0414272D0 (en) * 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
CN101072577B (zh) 2004-10-07 2013-12-18 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
AR063384A1 (es) 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
US8716437B2 (en) 2007-12-07 2014-05-06 Steven A. Goldstein Identification of toxin ligands
WO2010017632A1 (en) 2008-08-13 2010-02-18 The University Of British Columbia Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
EP2948559A1 (en) 2015-12-02
HUE039465T2 (hu) 2019-01-28
AU2014209227B2 (en) 2017-11-23
NZ709913A (en) 2019-05-31
US20190062383A1 (en) 2019-02-28
CN104937105A (zh) 2015-09-23
SMT201800357T1 (it) 2018-09-13
SG11201505508TA (en) 2015-08-28
IL239927B (en) 2020-10-29
JP2016505639A (ja) 2016-02-25
EP2948559B1 (en) 2018-05-02
US20140255401A1 (en) 2014-09-11
ES2671434T3 (es) 2018-06-06
UA117824C2 (uk) 2018-10-10
IL239927A0 (en) 2015-08-31
WO2014116937A1 (en) 2014-07-31
DK2948559T3 (en) 2018-05-28
US10179808B2 (en) 2019-01-15
MX365987B (es) 2019-06-20
EA201591380A1 (ru) 2015-12-30
CA2898496A1 (en) 2014-07-31
KR20150108912A (ko) 2015-09-30
PT2948559T (pt) 2018-07-24
MX2015009632A (es) 2015-11-30
JP6469590B2 (ja) 2019-02-13
PH12015501627B1 (en) 2020-12-11
RS57422B1 (sr) 2018-09-28
HRP20181055T1 (hr) 2018-09-07
EP2948559A4 (en) 2016-10-19
ZA201506131B (en) 2017-06-28
EA037308B1 (ru) 2021-03-10
LT2948559T (lt) 2018-06-25
PH12015501627A1 (en) 2015-09-21
KR102268830B1 (ko) 2021-06-24
SI2948559T1 (en) 2018-08-31
TR201809377T4 (tr) 2018-07-23
BR112015017795A2 (pt) 2017-11-21
CY1120481T1 (el) 2019-07-10
AU2014209227A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IL267681B (en) Selective grp94 inhibitors and uses thereof
PL2948559T3 (pl) Antagonisty kv1.3 i sposoby zastosowania
PL3411358T3 (pl) Podstawiony związek piperydynowy i jego zastosowanie
IL245036B (en) Pesticidal compositions and related methods
ME02917B (me) Kombinacija dr5 agoniste i anti-pd--1 antagoniste i načini primjene
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
PL3060275T3 (pl) Wstrzykiwacz i sposób montażu
PL4071639T3 (pl) Urządzenie i sposób konfiguracji dostępu do aplikacji
PT3052485T (pt) Compostos heterocíclicos e suas utilizações
PL2970123T3 (pl) Sól omekamtywu mekarbilu i sposób otrzymywania soli
EP2989214A4 (en) IN SITU INTERACTION DETERMINATION
DK3038654T3 (da) Ny anvendelse
PL3030519T3 (pl) Trójpierścieniowe związki benzoksaborolu i ich zastosowania
PL3091003T3 (pl) Pochodna 1,2‑naftochinonu i sposób jej przygotowania
HRP20181291T1 (hr) Heterobicikloarilni inhibitori rorc2 i njihova upotreba
DK3052522T3 (da) Anti-sox 10 antistofsystemer og -fremgangsmåder
DK3068505T3 (da) Spillesystem og -fremgangsmåde
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
PL3041454T5 (pl) Mieszanina proszków, zastosowanie mieszaniny proszków i urządzenie do rozpylania proszków
BR112016000450A2 (pt) oscilador, e método
PL2958558T3 (pl) Sposoby i kompozycje do leczenia białaczki
EP3048883C0 (en) PESTICIDE COMPOSITION AND ASSOCIATED PROCESS
LT3066091T (lt) Nmda antagonistų pirmtakai
EP2989568A4 (en) DETERMINING THE IMPORTANCE OF ATTRIBUTES